Chatsworth, CA-based North American Scientific (NAS) has launched ClearPath, a multicatheter breast brachytherapy device.
ClearPath is placed through a single incision and is designed to conform to the resection cavity following lumpectomy, allowing for more conformal radiation dose distribution during treatment. It also is intended to accommodate either high- or low-dose-rate treatments.
NAS has received 510(k) approval from the U.S. Food and Drug Administration for a low-dose-rate or continuous-release treatment utilizing the company's Prospera brachytherapy seeds. A 510(k) application to market the high-dose-rate version of ClearPath is pending.
By AuntMinnie.com staff writers
November 8, 2006
Related Reading
Cutrer to step down as NAS president/CEO, November 3, 2006
NAS gets nomosSTAT install, October 19, 2006
Losses rise, revenues down in NAS' Q3, September 8, 2006
NAS nets FDA nod, July 25, 2006
NAS back in compliance with Nasdaq, June 29, 2006
Copyright © 2006 AuntMinnie.com
